RISPERIDEX 3 MG

Šalis: Izraelis

kalba: anglų

Šaltinis: Ministry of Health

Nusipirk tai dabar

Veiklioji medžiaga:

RISPERIDONE

Prieinama:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC kodas:

N05AX08

Vaisto forma:

TABLETS

Sudėtis:

RISPERIDONE 3 MG

Vartojimo būdas:

PER OS

Recepto tipas:

Required

Pagaminta:

DEXCEL LTD, ISRAEL

Farmakoterapinė grupė:

RISPERIDONE

Gydymo sritis:

RISPERIDONE

Terapinės indikacijos:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years.Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Leidimo data:

2021-05-31

Dokumentai kitomis kalbomis

Pakuotės lapelis Pakuotės lapelis arabų 10-11-2020
Pakuotės lapelis Pakuotės lapelis hebrajų 23-05-2019

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją